EMERGING PUBLIC BIOTECH

ARCTURUS THERAPEUTICS HOLDINGS INC (ARCT)

San Diego, United States · North America
RARE DISEASE
RESPIRATORY
EMERGING PUBLIC BIOTECH
HEADQUARTERS
San Diego, United States
TICKER
ARCT
SEGMENT
Emerging Public Biotech
THERAPY AREAS
Rare Disease, Respiratory
KEY PRODUCTS
PRODUCTDETAILS
Qutavina
Nouryant
Crysvita
Poteligeo
Preotact
COMPANY OVERVIEW

Arcturus Therapeutics Holdings Inc., a messenger RNA medicines company, focuses on the development of liver and respiratory rare disease therapeutics. Its technology platforms include STARR, a self-amplifying mRNA technology platform, and LUNAR, a lipid-mediated delivery system. The company also develops ARCT-032 (LUNAR-CF), an mRNA therapeutic candidate for cystic fibrosis that is in Phase 2 clinical development; and ARCT-810 (LUNAR-OTC), which is in Phase 2 clinical development to address ornithine transcarbamylase (OTC) deficiency. In addition, it develops KOSTAIVE, a self-amplifying RNA vaccine for COVID-19; ARCT-2138 (LUNAR-FLU), which is in Phase1 clinical trial for the treatment of seasonal influenza; and ARCT-2304 (LUNAR-H5N1) that is in Phase1 clinical trial for the treatment of P…

ARCTURUS THERAPEUTICS HOLDINGS INC — FULL INTELLIGENCE

Live regulatory signals, patent cliffs, financials, tariff exposure and pipeline — all free on PharmaSignal.

OPEN PLATFORM →